Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer's Disease

J Alzheimers Dis. 2020;77(3):1117-1127. doi: 10.3233/JAD-200441.

Abstract

Background: Lipids have important structural roles in cell membranes and changes to these membrane lipids may influence β- and γ-secretase activities and thus contribute to Alzheimer's disease (AD) pathology.

Objective: To explore baseline plasma lipid profiling in participants with mild cognitive impairment (MCI) with and without AD pathology.

Methods: We identified 261 plasma lipids using reversed-phase liquid chromatography/mass spectrometry in cerebrospinal fluid amyloid positive (Aβ+) or negative (Aβ-) participants with MCI as compared to controls. Additionally, we analyzed the potential associations of plasma lipid profiles with performance on neuropsychological tests at baseline and after two years.

Results: Sphingomyelin (SM) concentrations, particularly, SM(d43:2), were lower in MCI Aβ+ individuals compared to controls. Further, SM(d43:2) was also nominally reduced in MCI Aβ+ individuals compared to MCI Aβ-. No plasma lipids were associated with performance on primary neuropsychological tests at baseline or between the two time points after correction for multiple testing.

Conclusion: Reduced plasma concentrations of SM were associated with AD.

Keywords: Alzheimer’s disease; lipid; mild cognitive impairment; sphingomyelin.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / blood*
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / epidemiology
  • Biomarkers / blood
  • Cognitive Dysfunction / blood*
  • Cognitive Dysfunction / diagnosis*
  • Cognitive Dysfunction / epidemiology
  • Cohort Studies
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Norway / epidemiology
  • Peptide Fragments / blood
  • Sphingomyelins / blood*

Substances

  • Biomarkers
  • Peptide Fragments
  • Sphingomyelins